12 results on '"Meng, Lu"'
Search Results
2. A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy.
- Author
-
Meng, Lu, Zha, Jialu, Zhou, Bingjie, Cao, Long, Jiang, Congli, Zhu, Yuanfei, Li, Teng, Lu, Lu, Zhang, Junqi, Yang, Heng, Feng, Jian, Gu, Zhifeng, Tang, Hong, Jiang, Lubin, Li, Dianfan, Lavillette, Dimitri, and Zhang, Xiaoming
- Subjects
- *
SARS-CoV-2 , *IMMUNOGLOBULINS , *MONOCLONAL antibodies , *SARS-CoV-2 Omicron variant , *TREATMENT effectiveness , *X-ray crystallography , *COVID-19 - Abstract
Neutralizing antibodies (nAbs) are important assets to fight COVID-19, but most existing nAbs lose the activities against Omicron subvariants. Here, we report a human monoclonal antibody (Ab08) isolated from a convalescent patient infected with the prototype strain (Wuhan-Hu-1). Ab08 binds to the receptor-binding domain (RBD) with pico-molar affinity (230 pM), effectively neutralizes SARS-CoV-2 and variants of concern (VOCs) including Alpha, Beta, Gamma, Mu, Omicron BA.1 and BA.2, and to a lesser extent for Delta and Omicron BA.4/BA.5 which bear the L452R mutation. Of medical importance, Ab08 shows therapeutic efficacy in SARS-CoV-2-infected hACE2 mice. X-ray crystallography of the Ab08-RBD complex reveals an antibody footprint largely in the β-strand core and away from the ACE2-binding motif. Negative staining electron-microscopy suggests a neutralizing mechanism through which Ab08 destructs the Spike trimer. Together, our work identifies a nAb with therapeutic potential for COVID-19. Author summary: To fight against SARS-CoV-2 Omicron subvariants, we screened and selected one human monoclonal antibody (Ab08) previously isolated from a convalescent patient infected with the SARS-CoV-2 prototype strain (Wuhan-Hu-1). The features of Ab08 are as followed: (1) Ab08 can effectively neutralize SARS-CoV-2 and variants of concern (VOCs) including Alpha, Beta, Gamma, Mu, Omicron BA.1 and BA.2, and to a lesser extent, Delta and Omicron BA.4/BA.5. (2) Ab08 can act as a therapeutic agent in SARS-CoV-2-infected hACE2 mice which are highly susceptible to infection. (3) Ab08 could destruct the Spike trimer which is essential for SARS-CoV-2 entry into the host cells. Together, our work identifies an effective neutralizing antibody with therapeutic potential for COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Using a Cloud-Based Machine Learning Classification Tree Analysis to Understand the Demographic Characteristics Associated With COVID-19 Booster Vaccination Among Adults in the United States.
- Author
-
Meng, Lu, Fast, Hannah E, Saelee, Ryan, Zell, Elizabeth, Murthy, Bhavini Patel, Murthy, Neil Chandra, Lu, Peng-Jun, Shaw, Lauren, Harris, LaTreace, Gibbs-Scharf, Lynn, and Chorba, Terence
- Abstract
A tree model identified adults age ≤34 years, Johnson & Johnson primary series recipients, people from racial/ethnic minority groups, residents of nonlarge metro areas, and those living in socially vulnerable communities in the South as less likely to be boosted. These findings can guide clinical/public health outreach toward specific subpopulations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Lift the veil of rumors: the impact of the characteristics of information sources on the effectiveness of rumors spreading.
- Author
-
Meng, Lu, Li, Tongmao, Huang, Xin, and Li, Shaobo
- Subjects
- *
INFORMATION resources , *RUMOR , *QUANTITATIVE research , *INFORMATION theory , *COVID-19 pandemic - Abstract
Purpose: This paper aims to investigate the impacts of rumors' information characteristics on people's believing and spreading of rumors online. Design/methodology/approach: This study employed a mixed-methods approach by combining qualitative and quantitative methods. In study 1, the authors explored different types of rumors and their information source characteristics through qualitative research. In study 2, the authors utilized the findings from study 1 to develop an empirical model to verify the impact of these characteristics on the public's behaviors of believing and spreading rumors by content analysis and quantitative research. Findings: The results show that five information source characteristics – credibility, professionalism, attractiveness, mystery and concreteness – influence the spreading effect of different types of rumors. Research limitations/implications: This study contributes to rumor spreading research by deepening the theory of information source characteristics and adding to the emerging literature on the COVID-19 pandemic. Practical implications: Insights from this research offer important practical implications for policymakers and online-platform operators by highlighting how to suppress the spread of rumors, particularly those associated with COVID-19. Originality/value: This research introduces the theory of information source characteristics into the field of rumor spreading and adopts a mixed-methods approach, taking COVID-19 rumors as a typical case, which provides a unique perspective for a deeper understanding of rumor spreading's antecedences. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China.
- Author
-
An Tang, Zhen-dong Tong, Hong-ling Wang, Ya-xin Dai, Ke-feng Li, Jie-nan Liu, Wen-jie Wu, Chen Yuan, Meng-lu Yu, Peng Li, Jian-bo Yan, Tang, An, Tong, Zhen-Dong, Wang, Hong-Ling, Dai, Ya-Xin, Li, Ke-Feng, Liu, Jie-Nan, Wu, Wen-Jie, Yuan, Chen, and Yu, Meng-Lu
- Subjects
- *
COVID-19 , *RESPIRATORY infections - Abstract
We report an asymptomatic child who was positive for a coronavirus by reverse transcription PCR in a stool specimen 17 days after the last virus exposure. The child was virus positive in stool specimens for at least an additional 9 days. Respiratory tract specimens were negative by reverse transcription PCR. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. COVID-19 Vaccine Initiation and Dose Completion During the SARS-CoV-2 Delta Variant Surge in the United States, December 2020–October 2021.
- Author
-
Murthy, Neil, Saelee, Ryan, Patel Murthy, Bhavini, Meng, Lu, Shaw, Lauren, Gibbs-Scharf, Lynn, Harris, LaTreace, Chorba, Terence, and Zell, Elizabeth
- Subjects
- *
GENETIC mutation , *COVID-19 , *COVID-19 vaccines , *TREATMENT effectiveness , *HOSPITAL care , *DESCRIPTIVE statistics - Abstract
Objectives: In summer 2021, the number of COVID-19–associated hospitalizations in the United States increased with the surge of the SARS-CoV-2 Delta variant. We assessed how COVID-19 vaccine initiation and dose completion changed during the Delta variant surge, based on jurisdictional vaccination coverage before the surge. Methods: We analyzed COVID-19 vaccination data reported to the Centers for Disease Control and Prevention. We classified jurisdictions (50 states and the District of Columbia) into quartiles ranging from high to low first-dose vaccination coverage among people aged ≥12 years as of June 30, 2021. We calculated first-dose vaccination coverage as of June 30 and October 31, 2021, and stratified coverage by quartile, age (12-17, 18-64, ≥65 years), and sex. We assessed dose completion among those who initiated a 2-dose vaccine series. Results: Of 51 jurisdictions, 15 reached at least 70% vaccination coverage before the Delta variant surge (ie, as of June 30, 2021), while 35 reached that goal as of October 31, 2021. Jurisdictions in the lowest quartile of vaccination coverage (44.9%-54.9%) had the greatest absolute (9.7%-17.9%) and relative (18.1%-39.8%) percentage increase in vaccination coverage during July 1–October 31, 2021. Of those who received the first dose during this period across all jurisdictions, nearly 1 in 5 missed the second dose. Conclusions: Although COVID-19 vaccination initiation increased during July 1–October 31, 2021, in jurisdictions in the lowest quartile of vaccination coverage, coverage remained below that of jurisdictions in the highest quartile of vaccination coverage before the Delta variant surge. Efforts are needed to improve access to and increase confidence in COVID-19 vaccines, especially in low-coverage areas. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Multisystem Inflammatory Syndrome in Adults: Case Finding Through Systematic Review of Electronic Medical Records.
- Author
-
Melgar, Michael, Haston, Julia, DeCuir, Jennifer, Cheng, Qi, Arnold, Kathryn E, Meng, Lu, Murphy, David J, Overton, Elizabeth, Hollberg, Julie, Tobin-D'Angelo, Melissa, Patel, Pragna, Campbell, Angela P, Godfred-Cato, Shana, and Belay, Ermias D
- Subjects
- *
ARTIFICIAL blood circulation , *HOSPICE care , *MULTISYSTEM inflammatory syndrome , *COVID-19 , *NOSOLOGY , *ADRENOCORTICAL hormones , *AGE distribution , *LEFT ventricular dysfunction , *RETROSPECTIVE studies , *ACQUISITION of data , *RACE , *ARTIFICIAL respiration , *SEX distribution , *HOSPITAL mortality , *RISK assessment , *HOSPITAL care , *SYMPTOMS , *MEDICAL records , *CRITICAL care medicine , *LONGITUDINAL method , *DISCHARGE planning - Abstract
Background Multisystem inflammatory syndrome in adults (MIS-A) is a severe condition temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods In this retrospective cohort study, we applied the US Centers for Disease Control and Prevention (CDC) case definition to identify diagnosed and undiagnosed MIS-A cases among adults discharged during April 2020–January 2021 from 4 Atlanta, Georgia hospitals affiliated with a single medical center. Non–MIS-A coronavirus disease 2019 (COVID-19) hospitalizations were identified using International Classification of Diseases, Tenth Revision, Clinical Modification encounter code U07.1. We calculated the ratio of MIS-A to COVID-19 hospitalizations, compared demographic characteristics of the 2 cohorts, and described clinical characteristics of MIS-A patients. Results We identified 11 MIS-A cases, none of which were diagnosed by the treatment team, and 5755 COVID-19 hospitalizations (ratio 1:523). Compared with patients with COVID-19, patients with MIS-A were more likely to be younger than 50 years (72.7% vs 26.1%, P <.01) and to be non-Hispanic Black (81.8% vs 50.0%, P =.04). Ten patients with MIS-A (90.9%) had at least 1 underlying medical condition. Two MIS-A patients (18.2%) had a previous episode of laboratory-confirmed COVID-19, occurring 37 and 55 days prior to admission. All MIS-A patients developed left ventricular systolic dysfunction. None had documented mucocutaneous involvement. All required intensive care, all received systemic corticosteroids, 8 (72.7%) required mechanical ventilation, 2 (18.2%) required mechanical cardiovascular circulatory support, and none received intravenous immunoglobulin. Two (18.2%) died or were discharged to hospice. Conclusions MIS-A is a severe but likely underrecognized complication of SARS-CoV-2 infection. Improved recognition of MIS-A is needed to quantify its burden and identify populations at highest risk. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. COVID-19 Vaccination and Intent for Vaccination of Adults With Reported Medical Conditions.
- Author
-
Lu, Peng-jun, Hung, Mei-Chuan, Jackson, Hannah L., Kriss, Jennifer L., Srivastav, Anup, Yankey, David, Santibanez, Tammy A., Lee, James Tseryuan, Meng, Lu, Razzaghi, Hilda, Black, Carla L., Elam-Evans, Laurie D., and Singleton, James A.
- Subjects
- *
COVID-19 vaccines , *VACCINATION , *VACCINATION coverage , *VACCINATION status , *COVID-19 - Abstract
Introduction: Individuals with certain medical conditions are at substantially increased risk for severe illness from COVID-19. The purpose of this study is to assess COVID-19 vaccination among U.S. adults with reported medical conditions.Methods: Data from the National Immunization Survey-Adult COVID Module collected during August 1-September 25, 2021 were analyzed in 2022 to assess COVID-19 vaccination status, intent, vaccine confidence, behavior, and experience among adults with reported medical conditions. Unadjusted and age-adjusted prevalence ratios (PRs and APRs) were generated using logistic regression and predictive marginals.Results: Overall, COVID-19 vaccination coverage with ≥1 dose was 81.8% among adults with reported medical conditions, and coverage was significantly higher compared with those without such conditions (70.3%) Among adults aged ≥18 years with medical conditions, COVID-19 vaccination coverage was significantly higher among those with a provider recommendation (86.5%) than those without (76.5%). Among all respondents, 9.2% of unvaccinated adults with medical conditions reported they were willing or open to vaccination. Adults who reported high risk medical conditions were more likely to report receiving a provider recommendation, often or always wearing masks during the last 7 days, concerning about getting COVID-19, thinking the vaccine is safe, and believing a COVID-19 vaccine is important for protection from COVID-19 infection than those without such conditions.Conclusions: Approximately 18.0% of those with reported medical conditions were unvaccinated. Receiving a provider recommendation was significantly associated with vaccination, reinforcing that provider recommendation is an important approach to increase vaccination coverage. Ensuring access to vaccine, addressing vaccination barriers, and increasing vaccine confidence can improve vaccination coverage among unvaccinated adults. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Trends in Treatments for Multisystem Inflammatory Syndrome in Children (MIS-C), United States, February 2020 – July 2021.
- Author
-
Abrams, Joseph Y, Belay, Ermias D, Godfred-Cato, Shana, Campbell, Angela P, Zambrano, Laura D, Kunkel, Amber, Miller, Allison D, Wu, Michael J, Meng, Lu, Shah, Ami B, and Oster, Matthew E
- Subjects
- *
STEROID drugs , *INTENSIVE care units , *VASOCONSTRICTORS , *PUBLIC health surveillance , *MULTISYSTEM inflammatory syndrome , *COVID-19 , *INTUBATION , *ANTICOAGULANTS , *ACQUISITION of data , *ARTIFICIAL respiration , *PLATELET aggregation inhibitors , *MEDICAL records , *CHILDREN - Abstract
Background Multisystem inflammatory syndrome in children (MIS-C) is a novel severe postinfectious condition associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The purpose of this report is to describe nationwide trends in the evolving clinical management of MIS-C. Methods Patients with MIS-C were reported from state and local jurisdictions to the Centers for Disease Control and Prevention's (CDC's) MIS-C national surveillance system. Patients' case reports were reviewed to ensure that they met the CDC MIS-C case definition and had sufficient data for analysis. The prevalence of use of treatments for MIS-C, temporal trends in use of these treatments, and frequency of administration of different treatment combinations were analyzed. Results There were 4470 patients meeting the MIS-C case definition with onset dates from 19 February 2020 to 31 July 2021. The proportion of patients admitted to an intensive care unit (ICU) has declined over time, from 78.7% in April 2020 to 57.5% in June 2021 (P = .001). The most common treatments were intravenous immunoglobulin (IVIG), given to 85.6% of patients; steroids (77.7%), and antiplatelet medications (73.7%); use of each of these treatments has increased over time, particularly in patients not requiring admission to an ICU (all P < .001). Older patients and non-Hispanic Black patients were more likely to receive additional modes of therapy including vasoactive medication, noninvasive respiratory support, anticoagulation medication, and intubation/mechanical ventilation. Conclusions IVIG, steroids, and antiplatelet medication have become increasingly utilized as standard treatment for MIS-C patients, while the use of other treatments may be contingent on the type and severity of clinical findings. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Multisystem Inflammatory Syndrome in Adults After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Coronavirus Disease 2019 (COVID-19) Vaccination.
- Author
-
Belay, Ermias D, Cato, Shana Godfred, Rao, Agam K, Abrams, Joseph, Wilson, W Wyatt, Lim, Sarah, Newton-Cheh, Christopher, Melgar, Michael, DeCuir, Jennifer, Webb, Brandon, Marquez, Paige, Su, John R, Meng, Lu, Grome, Heather N, Schlaudecker, Elizabeth, Talaat, Kawsar, Edwards, Kathryn, Barnett, Elizabeth, Campbell, Angela P, and Broder, Karen R
- Subjects
- *
COVID-19 , *MULTISYSTEM inflammatory syndrome , *COVID-19 vaccines , *SEVERITY of illness index , *DESCRIPTIVE statistics , *DRUG side effects - Abstract
Background Multisystem inflammatory syndrome in adults (MIS-A) was reported in association with the coronavirus disease 2019 (COVID-19) pandemic. MIS-A was included in the list of adverse events to be monitored as part of the emergency use authorizations issued for COVID-19 vaccines. Methods Reports of MIS-A patients received by the Centers for Disease Control and Prevention (CDC) after COVID-19 vaccines became available were assessed. Data collected on the patients included clinical and demographic characteristics and their vaccine status. The Vaccine Adverse Events Reporting System (VAERS) was also reviewed for possible cases of MIS-A. Results From 14 December 2020 to 30 April 2021, 20 patients who met the case definition for MIS-A were reported to CDC. Their median age was 35 years (range, 21–66 years), and 13 (65%) were male. Overall, 16 (80%) patients had a preceding COVID-19-like illness a median of 26 days (range 11–78 days) before MIS-A onset. All 20 patients had laboratory evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Seven MIS-A patients (35%) received COVID-19 vaccine a median of 10 days (range, 6–45 days) before MIS-A onset; 3 patients received a second dose of COVID-19 vaccine 4, 17, and 22 days before MIS-A onset. Patients with MIS-A predominantly had gastrointestinal and cardiac manifestations and hypotension or shock. Conclusions Although 7 patients were reported to have received COVID-19 vaccine, all had evidence of prior SARS-CoV-2 infection. Given the widespread use of COVID-19 vaccines, the lack of reporting of MIS-A associated with vaccination alone, without evidence of underlying SARS-CoV-2 infection, is reassuring. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Multisystem Inflammatory Syndrome in Children—United States, February 2020–July 2021.
- Author
-
Miller, Allison D, Zambrano, Laura D, Yousaf, Anna R, Abrams, Joseph Y, Meng, Lu, Wu, Michael J, Melgar, Michael, Oster, Matthew E, Cato, Shana E Godfred, Belay, Ermias D, Campbell, Angela P, and Group, MIS-C Surveillance Authorship
- Subjects
- *
MULTISYSTEM inflammatory syndrome - Abstract
Background Multisystem inflammatory syndrome in children (MIS-C) is a severe hyperinflammatory condition in persons aged <21 years associated with antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to describe MIS-C cases reported to Centers for Disease Control and Prevention's (CDC's) national surveillance since the coronavirus disease 2019 (COVID-19) pandemic began. Methods We included patients meeting the MIS-C case definition with onset date from 19 February 2020 through 31 July 2021, using CDC's MIS-C case report form, which collects information on demographics, clinical presentation, and laboratory results. Trends over time across 3 MIS-C pandemic waves were assessed using Cochran-Armitage test for categorical and Jonckheere-Terpstra test for continuous variables. Results Of 4901 reported cases, 4470 met inclusion criteria. Median patient age increased over time (P < .001), with a median of 9 years (interquartile range, 5–13 years) during the most recent (third) wave. Male predominance also increased (62% in third wave, P < .001). A significant (P < .001) increase in severe hematologic and gastrointestinal involvement was observed across the study period. Frequency of several cardiovascular complications (ie, cardiac dysfunction, myocarditis, and shock/vasopressor receipt) and renal failure declined (P < .001). Provision of critical care including mechanical ventilation (P < .001) and extracorporeal membrane oxygenation (ECMO; P = .046) decreased, as did duration of hospitalization and mortality (each P < .001). Conclusions Over the first 3 pandemic waves of MIS-C in the United States, cardiovascular complications and clinical outcomes including length of hospitalization, receipt of ECMO, and death decreased over time. These data serve as a baseline for monitoring future trends associated with SARS-CoV-2 B.1.617.2 (Delta) or other variants and increased COVID-19 vaccination among children. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Serologic and Cytokine Signatures in Children With Multisystem Inflammatory Syndrome and Coronavirus Disease 2019.
- Author
-
Lapp, Stacey A, Abrams, Joseph, Lu, Austin T, Hussaini, Laila, Kao, Carol M, Hunstad, David A, Rosenberg, Robert B, Zafferani, Marc J, Ede, Kaleo C, Ballan, Wassim, Laham, Federico R, Beltran, Yajira, Hsiao, Hui-Mien, Sherry, Whitney, Jenkins, Elan, Jones, Kaitlin, Horner, Anna, Brooks, Alyssa, Bryant, Bobbi, and Meng, Lu
- Subjects
- *
MULTISYSTEM inflammatory syndrome in children , *CORONAVIRUS diseases , *SARS-CoV-2 , *COVID-19 - Abstract
Background The serologic and cytokine responses of children hospitalized with multisystem inflammatory syndrome (MIS-C) vs coronavirus disease 2019 (COVID-19) are poorly understood. Methods We performed a prospective, multicenter, cross-sectional study of hospitalized children who met the Centers for Disease Control and Prevention case definition for MIS-C (n = 118), acute COVID-19 (n = 88), or contemporaneous healthy controls (n = 24). We measured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) immunoglobulin G (IgG) titers and cytokine concentrations in patients and performed multivariable analysis to determine cytokine signatures associated with MIS-C. We also measured nucleocapsid IgG and convalescent RBD IgG in subsets of patients. Results Children with MIS-C had significantly higher SARS-CoV-2 RBD IgG than children with acute COVID-19 (median, 2783 vs 146; P < .001), and titers correlated with nucleocapsid IgG. For patients with MIS-C, RBD IgG titers declined in convalescence (median, 2783 vs 1135; P = .010) in contrast to patients with COVID-19 (median, 146 vs 4795; P < .001). MIS-C was characterized by transient acute proinflammatory hypercytokinemia, including elevated levels of interleukin (IL) 6, IL-10, IL-17A, and interferon gamma (IFN-γ). Elevation of at least 3 of these cytokines was associated with significantly increased prevalence of prolonged hospitalization ≥8 days (prevalence ratio, 3.29 [95% CI, 1.17–9.23]). Conclusions MIS-C was associated with high titers of SARS-CoV-2 RBD IgG antibodies and acute hypercytokinemia with IL-6, IL-10, IL-17A, and IFN-γ. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.